{
    "clinical_study": {
        "@rank": "95875", 
        "arm_group": {
            "arm_group_label": "Main Cohort", 
            "description": "Subjects enrolled in this group will receive a full field digital mammogram, digital breast tomosynthesis exam and an automated whole breast ultrasound exam as part of their visit."
        }, 
        "brief_summary": {
            "textblock": "This study is investigating whether automated whole breast ultrasound can improve detection\n      of cancer in breast cancer screening when used as a supplement to mammography or as a\n      supplement to digital breast tomosynthesis"
        }, 
        "brief_title": "Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able and willing to provide signed declaration of informed consent or have a legally\n             authorized representative provide signed declaration of informed consent for\n             participation in all study procedures;\n\n          -  Women aged \u226518 years at the time of enrollment;*\n\n          -  Women with a previous determination of dense breasts determined by mammogram as\n             heterogeneously dense or extremely dense; AND\n\n          -  At moderately increased or high risk (>15% lifetime risk) for breast cancer based on\n             meeting one or more of the ACS criteria 1:\n\n               1. BRCA1 or BRCA2 gene mutation;\n\n               2. first-degree relative with BRCA1 or BRCA2 gene mutation (based on subject\n                  self-report) and have not had genetic testing themselves;\n\n               3. radiation therapy to the chest between ages 10 and 30 years;\n\n               4. Li-Fraumeni syndrome, Cowden syndrome, or Bannayan-Riley-Ruvalcaba syndrome, or\n                  one of these syndromes in a first-degree relative;\n\n               5. previous diagnosis of breast cancer, ductal carcinoma in situ (DCIS), lobular\n                  carcinoma in situ, atypical ductal hyperplasia, or atypical lobular hyperplasia.\n\n        Exclusion Criteria:\n\n          -  Have been screened using any breast imaging technology in <12 months immediately\n             prior to enrollment;\n\n          -  Exhibit breast cancer symptoms according to assessment by the subject's health care\n             provider within one year prior to enrollment;\n\n          -  Diagnosed with breast cancer, with or without metastasis, within one year prior to\n             enrollment;\n\n          -  Are currently pregnant based on urine pregnancy test;*\n\n          -  Present with contraindications to any imaging examination required in the study\n             protocol;\n\n          -  Have breast implants;\n\n          -  Are lactating."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects will be selected from the patients arriving at the clinic for yearly breast\n        cancer screening exams"
            }
        }, 
        "enrollment": {
            "#text": "650", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02042456", 
            "org_study_id": "124.03-2013-GES-0003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Main Cohort", 
                "description": "digital breast tomosynthesis technology", 
                "intervention_name": "Digital Breast Tomosynthesis", 
                "intervention_type": "Device", 
                "other_name": "GE SenoClaire DBT with V-Preview"
            }, 
            {
                "arm_group_label": "Main Cohort", 
                "description": "Automated Whole Breast Ultrasound", 
                "intervention_name": "Automated Whole Breast Ultrasound", 
                "intervention_type": "Device", 
                "other_name": "Invenia ABUS"
            }, 
            {
                "arm_group_label": "Main Cohort", 
                "intervention_name": "Full Field Digital Mammography", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "breast cancer", 
            "dense breasts", 
            "mammography screening", 
            "Screening techniques", 
            "women"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "contact": {
                "email": "skolb@seattlecca.org", 
                "last_name": "Suzanne Kolb", 
                "phone": "206-288-6321"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "University of Washington Seattle Cancer Care Alliance"
            }, 
            "investigator": [
                {
                    "last_name": "Constance Lehman, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Janie Lee, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Christoph Lee, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Habibollah Rahbar, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John Scheel, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Abnormal interpretation rates for each modality (FFDM and DBT+V-Preview, with and without ABUS+V-Preview).", 
            "measure": "Abnormal interpretation rate", 
            "safety_issue": "No", 
            "time_frame": "One Year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02042456"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Sensitivity will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS", 
                "measure": "Sensitivity", 
                "safety_issue": "No", 
                "time_frame": "One Year"
            }, 
            {
                "description": "Specificity will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS", 
                "measure": "Specificity", 
                "safety_issue": "No", 
                "time_frame": "One Year"
            }, 
            {
                "description": "Cancer Rate will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS", 
                "measure": "Cancer Rate", 
                "safety_issue": "No", 
                "time_frame": "One Year"
            }, 
            {
                "description": "Positive Predictive Value will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS", 
                "measure": "Positive Predictive Value", 
                "safety_issue": "No", 
                "time_frame": "One Year"
            }, 
            {
                "description": "Negative Predictive Value will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS", 
                "measure": "Negative Predictive Value", 
                "safety_issue": "No", 
                "time_frame": "One Year"
            }
        ], 
        "source": "GE Healthcare", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GE Healthcare", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}